489 related articles for article (PubMed ID: 18525041)
1. Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Parving HH; Persson F; Lewis JB; Lewis EJ; Hollenberg NK;
N Engl J Med; 2008 Jun; 358(23):2433-46. PubMed ID: 18525041
[TBL] [Abstract][Full Text] [Related]
2. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.
Persson F; Lewis JB; Lewis EJ; Rossing P; Hollenberg NK; Parving HH;
Diabetes Care; 2010 Nov; 33(11):2304-9. PubMed ID: 20693353
[TBL] [Abstract][Full Text] [Related]
3. Aliskiren and dual therapy in type 2 diabetes mellitus.
Ingelfinger JR
N Engl J Med; 2008 Jun; 358(23):2503-5. PubMed ID: 18525047
[No Abstract] [Full Text] [Related]
4. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
[TBL] [Abstract][Full Text] [Related]
5. Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.
Persson F; Lewis JB; Lewis EJ; Rossing P; Hollenberg NK; Parving HH
Clin J Am Soc Nephrol; 2011 May; 6(5):1025-31. PubMed ID: 21350110
[TBL] [Abstract][Full Text] [Related]
6. Aliskiren combined with losartan in diabetes and nephropathy.
Lindner T
N Engl J Med; 2008 Sep; 359(10):1068-9; author reply 1069-70. PubMed ID: 18777612
[No Abstract] [Full Text] [Related]
7. Aliskiren combined with losartan in diabetes and nephropathy.
Panesar M; Damodar A
N Engl J Med; 2008 Sep; 359(10):1068; author reply 1069-70. PubMed ID: 18768954
[No Abstract] [Full Text] [Related]
8. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
Oparil S; Yarows SA; Patel S; Fang H; Zhang J; Satlin A
Lancet; 2007 Jul; 370(9583):221-229. PubMed ID: 17658393
[TBL] [Abstract][Full Text] [Related]
10. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren.
Stanton A; Jensen C; Nussberger J; O'Brien E
Hypertension; 2003 Dec; 42(6):1137-43. PubMed ID: 14597641
[TBL] [Abstract][Full Text] [Related]
11. Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.
Dalla Vestra M; Simioni N; Masiero A
Minerva Endocrinol; 2009 Dec; 34(4):333-8. PubMed ID: 20046162
[TBL] [Abstract][Full Text] [Related]
12. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
13. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial.
Persson F; Rossing P; Reinhard H; Juhl T; Stehouwer CD; Schalkwijk C; Danser AH; Boomsma F; Frandsen E; Parving HH
Diabetologia; 2010 Aug; 53(8):1576-80. PubMed ID: 20480132
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren combined with losartan in diabetes and nephropathy.
Anderson S; Komers R
N Engl J Med; 2008 Sep; 359(10):1069; author reply 1069-70. PubMed ID: 18777613
[No Abstract] [Full Text] [Related]
15. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria.
Delea TE; Sofrygin O; Palmer JL; Lau H; Munk VC; Sung J; Charney A; Parving HH; Sullivan SD
J Am Soc Nephrol; 2009 Oct; 20(10):2205-13. PubMed ID: 19762496
[TBL] [Abstract][Full Text] [Related]
18. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Jordan J; Engeli S; Boye SW; Le Breton S; Keefe DL
Hypertension; 2007 May; 49(5):1047-55. PubMed ID: 17353513
[TBL] [Abstract][Full Text] [Related]
19. Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials.
Stanton AV; Gradman AH; Schmieder RE; Nussberger J; Sarangapani R; Prescott MF
Hypertension; 2010 Jan; 55(1):54-60. PubMed ID: 19917876
[TBL] [Abstract][Full Text] [Related]
20. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
